Introduction
Patients with an ileostomy often have impaired quality of life, sodium depletion, secondary hyperaldosteronism, and other organ-specific pathologies. The osmolality of oral supplements influences ileostomy output and sodium loss.
Aims & Methods
We hypothesized the existence of an osmolality range where fluid absorption and secondary natriuresis are optimal. This was a single-center, quasi-randomized crossover intervention study, including patients with an ileostomy and no home parenteral support. After an 8-hour fasting period, each patient ingested 500 mL of between 3 and 18 different oral supplements and a standardized meal during separate intervention periods, followed by a 6-hour collection of ileostomy and urine outputs. The primary outcome was 6-hour ileostomy output.
Results
A total of 14 adult patients with an ileostomy (median age 64.5 years (range 22 - 77)) were included. The association between osmolalities in the entire range of 5-1352 mOsm/kg and ileostomy output forecasted an S-curve. In a mixed-effect model with the patients as a random effect, we observed a linear association between the osmolality of oral supplements in the range of 290-600 mOsm/kg and ileostomy output, which increased with 57g/6 hours (95% CI 21 – 94) when the oral supplement osmolality increased 100 mOsm/kg (p<0.005).
Conclusion
Osmolality in oral supplements correlated with ileostomy output in patients with an ileostomy. Our results indicate that patients with an ileostomy may benefit from increasing their ingestion of oral supplements with osmolalities between 100 and 290 mOsm /kg. We suggest this range is called the Goldilocks zone, indicating optimal fluid absorption.
Disclosure
This work was supported by Helga and Peter Kornings fond, Aarhus, Denmark, and the A. P. Møller fonden, Copenhagen, Denmark. Josephine R. Quist have received financial support from Aarhus University for PhD courses and biostatistical advisory service (BIAS). Aarhus University have not had any input to or influence on the manuscript preparation. CH received funding from Novo Nordisk Foundation (grant no. NNF22OC0074080).